Authors’ Reply to Alatorre et al.: “Cost Effectiveness of Guanfacine Extended-Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder: Application of a Matching-Adjusted Indirect Comparison”

Documenti analoghi

• Comparative Efficacy of Guanfacine Extended Release Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents: Applying Matching-Adjusted Indirect Comparison Methodology
  di: Sikirica, Vanja, et al.
  Pubblicazione: (2013)
• Cost Effectiveness of Guanfacine Extended Release as an Adjunctive Therapy to a Stimulant Compared with Stimulant Monotherapy for the Treatment of Attention-Deficit Hyperactivity Disorder in Children and Adolescents
  di: Sikirica, Vanja, et al.
  Pubblicazione: (2012)
• Concomitant Pharmacotherapy of Psychotropic Medications in EU Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
  di: Sikirica, Vanja, et al.
  Pubblicazione: (2013)
• Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison
  di: Joseph, Alain, et al.
  Pubblicazione: (2017)
• Caregiver perspective on pediatric attention-deficit/hyperactivity disorder: medication satisfaction and symptom control
  di: Fridman, Moshe, et al.
  Pubblicazione: (2017)